x
Filter:
Filters applied
- ACMG Statements and Guidelines
- Toriello, Helga VRemove Toriello, Helga V filter
Publication Date
Please choose a date range between 2005 and 2020.
Keyword
- chromosome anomalies1
- congenital anomalies1
- consanguinity1
- folic acid1
- folic acid supplementation1
- fortification1
- genetic counseling1
- genetic evaluation1
- genetic referral1
- genetic screening1
- homocysteine1
- homozygosity1
- laboratory guideline1
- MTHFR polymorphism1
- mutation1
- neural tube defects1
- paternal age1
- preconceptional testing1
- prenatal diet1
- prenatal testing1
- prevention1
- supplementation1
- thermolabile variant1
- thrombophilia1
- thrombosis1
ACMG Statements and Guidelines
These online statements and guidelines are definitive and may be cited using the digital object identifier (DOI). These recommendations are designed primarily as an educational resource for medical geneticists and other healthcare providers to help them provide quality medical genetics services; they should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Please refer to the leading disclaimer in each document for more information.
8 Results
- AddendumOpen Archive
Addendum: ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing
Genetics in MedicineVol. 22Issue 12p2125Published in issue: December, 2020- Michael T. Bashford
- Scott E. Hickey
- Cynthia J. Curry
- Helga V. Toriello
- The American College of Medical Genetics and Genomics (ACMG) Professional Practice and Guidelines Committee
Cited in Scopus: 0This is an addendum to the article available online at https://doi.org/10.1038/gim.2012.165 . - CorrectionOpen Archive
Correction: Addendum: ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing
Genetics in MedicineVol. 22Issue 9p1568Published in issue: September, 2020- Michael T. Bashford
- Scott E. Hickey
- Cynthia J. Curry
- Helga V. Toriello
Cited in Scopus: 0An amendment to this paper has been published and can be accessed via a link at the top of the paper. - ACMG Practice GuidelineOpen Archive
ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing
Genetics in MedicineVol. 15Issue 2p153–156Published in issue: February, 2013- Scott E. Hickey
- Cynthia J. Curry
- Helga V. Toriello
Cited in Scopus: 106MTHFR polymorphism testing is frequently ordered by physicians as part of the clinical evaluation for thrombophilia. It was previously hypothesized that reduced enzyme activity of MTHFR led to mild hyperhomocysteinemia which led to an increased risk for venous thromboembolism, coronary heart disease, and recurrent pregnancy loss. Recent meta-analyses have disproven an association between hyperhomocysteinemia and risk for coronary heart disease and between MTHFR polymorphism status and risk for venous thromboembolism. - ACMG Standards and GuidelinesOpen Archive
American College of Medical Genetics and Genomics: standards and guidelines for documenting suspected consanguinity as an incidental finding of genomic testing
Genetics in MedicineVol. 15Issue 2p150–152Published in issue: February, 2013- Catherine W. Rehder
- Karen L. David
- Betsy Hirsch
- Helga V. Toriello
- Carolyn M. Wilson
- Hutton M. Kearney
Cited in Scopus: 74Genomic testing, including single-nucleotide polymorphism–based microarrays and whole-genome sequencing, can detect long stretches of the genome that display homozygosity. The presence of these segments, when distributed across multiple chromosomes, can indicate a familial relationship between the proband’s parents. This article describes the detection of possible consanguinity by genomic testing and the factors confounding the inference of a specific parental relationship. It is designed to guide the documentation of suspected consanguinity by clinical laboratory professionals and to alert laboratories to the need to establish a reporting policy in conjunction with their ethics review committee and legal counsel. - ACMG Practice GuidelinesOpen Archive
Policy statement on folic acid and neural tube defects
Genetics in MedicineVol. 13Issue 6p593–596Published in issue: June, 2011- Helga V. Toriello
- for the Policy and Practice Guideline Committee of the American College of Medical Genetics.
Cited in Scopus: 28It now recognized that the use of folate fortification and/or supplementation before initiation of pregnancy can impact the risk of the fetus developing a neural tube defect. This document serves to update the policy statement issued by the American College of Medical Genetics and published in 2005. - ACMG Practice GuidelinesOpen Archive
Statement on guidance for genetic counseling in advanced paternal age
Genetics in MedicineVol. 10Issue 6p457–460Published in issue: June, 2008- Helga V. Toriello
- Jeanne M. Meck
- for the Professional Practice and Guidelines Committee
Cited in Scopus: 118In 1996, a practice guideline on genetic counseling for advanced paternal age was published. The current document updates the state of knowledge of advanced paternal age effects on single gene mutations, chromosome anomalies, and complex traits. - ACMG Practice GuidelinesOpen Archive
Indications for genetic referral: a guide for healthcare providers
Genetics in MedicineVol. 9Issue 6p385–389Published in issue: June, 2007- Beth A. Pletcher
- Helga V. Toriello
- Sarah J. Noblin
- Laurie H. Seaver
- Deborah A. Driscoll
- Robin L. Bennett
- and others
Cited in Scopus: 40Disclaimer: This guideline is designed primarily as an educational resource for medical geneticists and other healthcare providers to help them provide quality medical genetic services. Adherence to this guideline does not necessarily assure a successful medical outcome. This guideline should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the geneticist should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen. - ACMG Practice GuidelinesOpen Archive
Folic acid and neural tube defects
Genetics in MedicineVol. 7Issue 4p283–284Published in issue: April, 2005- Helga V. Toriello
- for the Professional Practice and Guidelines Committee
Cited in Scopus: 16Major congenital anomalies occur in 2% to 3% of live births. Neural tube defects (NTDs), cleft lip and palate, and cardiac anomalies are some of the most common. NTDs are a group of serious birth defects that affect the developing nervous system and include anencephaly, spina bifida, and encephalocele. Birth records suggest that about 2500 babies with these birth defects, or 1 to 2 per 1000, are born each year in the United States. Some affected pregnancies are spontaneously or electively aborted.
